Compare Adaptive Biotechnologies Corp (ADPT) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Unity Software Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.01 (market cap $3.33B), while Unity Software Inc trades at $28.76 (market cap $12.95B). The key difference: Unity Software Inc is far larger — about 3.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | U | |
|---|---|---|
Market Cap | $3.33B | $12.95B |
Sector | Health | Technology |
52-Week High | $22.37 | $49.47 |
52-Week Low | $10.24 | $17.13 |
Enterprise Value | $3.19B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Unity Software (U) trades at $29.66, up 1.16% today, with a bullish technical outlook and strong analyst support. The stock shows improving fundamentals with revenue stable at $1.85 billion in 2025 and narrowing losses, while operating cash flow grew to $423 million. Recent news highlights Unity's strategic pivot toward AI-driven advertising and developer tools, boosting investor confidence despite ongoing net losses.
The outlook is cautiously optimistic with a consensus price target of $36.50 implying 23% upside. Key opportunities include AI integration and margin expansion, but risks persist from competitive pressures, high debt, and profitability challenges. Investors should weigh growth potential against execution risks in the evolving tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
